Compare CNXU & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNXU | NRXS |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 82.0M |
| IPO Year | 2025 | 2023 |
| Metric | CNXU | NRXS |
|---|---|---|
| Price | $3.10 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 329.9K | 140.1K |
| Earning Date | 02-03-2027 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $132.54 |
| Revenue Next Year | N/A | $138.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $2.95 | $2.21 |
| 52 Week High | $13.66 | $9.33 |
| Indicator | CNXU | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 55.65 |
| Support Level | $3.05 | $6.60 |
| Resistance Level | $4.36 | $7.75 |
| Average True Range (ATR) | 0.56 | 0.45 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 12.06 | 73.17 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).